Biotech Fund Sells $44.5 Million Stake in Erasca Following a 700% Share Price Rally
Paradigm Biocapital Advisors sold approximately 3.8 million shares of Erasca (NASDAQ:ERAS) for an estimated $44.52 million during Q1 2026, following the stock's massive 716.5% surge over the past year. The sale reduced its stake in Erasca to represent just 3.44% of Paradigm’s total AUM as reported in a recent SEC filing.
Tickers: $ERAS